| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9127013 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US8513263 | BAYER HEALTHCARE | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
Dec, 2029
(5 years from now) | |
| US10172861 | BAYER HEALTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| US10799505 | BAYER HEALTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Aug, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9676783 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US10774085 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US10047097 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US9447104 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US10005783 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US8865698 | BAYER HEALTHCARE | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US9782414 | BAYER HEALTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| US10045991 | BAYER HEALTHCARE | Methods of treating pediatric cancers |
Apr, 2037
(12 years from now) | |
| US10137127 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(12 years from now) | |
| US11191766 | BAYER HEALTHCARE | Methods of treating pediatric cancers |
Apr, 2037
(12 years from now) | |
| US10668072 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(12 years from now) | |
| US11484535 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(12 years from now) | |
Vitrakvi is owned by Bayer Healthcare.
Vitrakvi contains Larotrectinib Sulfate.
Vitrakvi has a total of 16 drug patents out of which 0 drug patents have expired.
Vitrakvi was authorised for market use on 26 November, 2018.
Vitrakvi is available in solution;oral dosage forms.
Vitrakvi can be used as method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution, method of treating solid tumors that exhibit an ntrk fusion gene in a pediatric patient, method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion, method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection, method of treating cancerous solid tumors, method of treating solid tumors that exhibit an ntrk gene fusion.
Drug patent challenges can be filed against Vitrakvi from 26 November, 2022.
The generics of Vitrakvi are possible to be released after 04 April, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-215) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-220) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-221) | Nov 26, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 26, 2023 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 26 November, 2022
Market Authorisation Date: 26 November, 2018
Treatment: Method of treating cancerous solid tumors; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; ...
Dosage: SOLUTION;ORAL
VITRAKVI family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9127013 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US8513263 | BAYER HLTHCARE | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
Dec, 2029
(5 years from now) | |
| US10172861 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| US10799505 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Aug, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10047097 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US9447104 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US9676783 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US8865698 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US10005783 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US10774085 | BAYER HLTHCARE | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(5 years from now) | |
| US10285993 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| US10813936 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
| US9782414 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(11 years from now) | |
Vitrakvi is owned by Bayer Hlthcare.
Vitrakvi contains Larotrectinib Sulfate.
Vitrakvi has a total of 13 drug patents out of which 0 drug patents have expired.
Vitrakvi was authorised for market use on 26 November, 2018.
Vitrakvi is available in capsule;oral dosage forms.
Vitrakvi can be used as method of treating lung cancer, undifferentiated sarcoma, or colorectal cancer that exhibits an ntrk gene fusion, method of treating solid tumors that exhibit an ntrk gene fusion in a pediatric patient, method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion, method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection, method of treating cancerous solid tumors, method of treating solid tumors that exhibit an ntrk gene fusion.
Drug patent challenges can be filed against Vitrakvi from 26 November, 2022.
The generics of Vitrakvi are possible to be released after 15 August, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-215) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-220) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-221) | Nov 26, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 26, 2023 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 26 November, 2022
Market Authorisation Date: 26 November, 2018
Treatment: Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating cancerous solid tumors; ...
Dosage: CAPSULE;ORAL
VITRAKVI family patents